SG11201502452RA - Inhibitors of histone demethylases - Google Patents
Inhibitors of histone demethylasesInfo
- Publication number
- SG11201502452RA SG11201502452RA SG11201502452RA SG11201502452RA SG11201502452RA SG 11201502452R A SG11201502452R A SG 11201502452RA SG 11201502452R A SG11201502452R A SG 11201502452RA SG 11201502452R A SG11201502452R A SG 11201502452RA SG 11201502452R A SG11201502452R A SG 11201502452RA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- histone demethylases
- demethylases
- histone
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261708806P | 2012-10-02 | 2012-10-02 | |
DKPA201200599 | 2012-10-02 | ||
US201361770050P | 2013-02-27 | 2013-02-27 | |
DKPA201370112 | 2013-02-27 | ||
PCT/EP2013/070457 WO2014053491A1 (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201502452RA true SG11201502452RA (en) | 2015-05-28 |
Family
ID=52781382
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703682YA SG10201703682YA (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
SG11201502452RA SG11201502452RA (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703682YA SG10201703682YA (en) | 2012-10-02 | 2013-10-01 | Inhibitors of histone demethylases |
Country Status (33)
Country | Link |
---|---|
US (3) | US20150203453A1 (en) |
EP (3) | EP2903968B1 (en) |
JP (2) | JP6530313B2 (en) |
KR (1) | KR102160320B1 (en) |
CN (2) | CN107434803B (en) |
AP (1) | AP2015008389A0 (en) |
AU (1) | AU2018200876C1 (en) |
BR (1) | BR112015007083A2 (en) |
CA (2) | CA2885969C (en) |
CL (1) | CL2015000829A1 (en) |
CR (1) | CR20150217A (en) |
CY (1) | CY1118695T1 (en) |
DK (1) | DK2903968T3 (en) |
EA (1) | EA030698B1 (en) |
ES (2) | ES2617905T3 (en) |
HK (3) | HK1207373A1 (en) |
HR (1) | HRP20170358T1 (en) |
HU (1) | HUE033380T2 (en) |
IL (2) | IL237831A (en) |
LT (1) | LT2903968T (en) |
MD (1) | MD20150043A2 (en) |
ME (1) | ME02597B (en) |
MX (1) | MX2015003959A (en) |
NZ (1) | NZ706635A (en) |
PE (1) | PE20150998A1 (en) |
PH (2) | PH12015500730A1 (en) |
PL (2) | PL2903968T3 (en) |
PT (2) | PT3023415T (en) |
RS (1) | RS55764B1 (en) |
SG (2) | SG10201703682YA (en) |
SI (2) | SI2903968T1 (en) |
SM (1) | SMT201700109B (en) |
WO (1) | WO2014053491A1 (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2885969C (en) | 2012-10-02 | 2021-04-06 | Epitherapeutics Aps | Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases |
US9650339B2 (en) | 2013-02-27 | 2017-05-16 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
EP3126345A1 (en) * | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
EA201790154A1 (en) | 2014-08-27 | 2017-08-31 | Джилид Сайэнс, Инк. | COMPOUNDS AND METHODS FOR INHIBITING HISTONAL DEMETYLASES |
CN107001330A (en) * | 2014-09-17 | 2017-08-01 | 赛尔基因昆蒂赛尔研究公司 | Histone demethylase inhibitors |
EP3453710B1 (en) | 2014-09-17 | 2022-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US10030017B2 (en) | 2014-09-17 | 2018-07-24 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CN107001358A (en) | 2014-10-29 | 2017-08-01 | 东亚St株式会社 | Adjust the new pyridine hepyramine compound of istone lysine demethylase (KDM) catalytic activity |
DK3212789T3 (en) * | 2014-10-31 | 2020-07-27 | Massachusetts Inst Technology | MASSIVE PARALLEL COMBINATORY GENETICS FOR CRISPR |
AU2016250099A1 (en) * | 2015-04-14 | 2017-10-12 | Gilead Sciences, Inc. | Methods of treating hepatitis B virus |
US10206930B2 (en) * | 2015-08-14 | 2019-02-19 | New York University | Methods for treating T-cell acute lymphoblastic leukemia |
WO2017099829A1 (en) | 2015-12-11 | 2017-06-15 | The General Hospital Corporation | Compositions and methods for treating drug-tolerant glioblastoma |
JP6883913B2 (en) | 2015-12-28 | 2021-06-09 | セルジーン クオンティセル リサーチ,インク. | Histone demethylase inhibitor |
WO2017161012A1 (en) * | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
WO2017198785A1 (en) * | 2016-05-18 | 2017-11-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Oxime derivatives useful as inhibitors of histone demethylase kdm4c |
BR112018073858A2 (en) | 2016-05-27 | 2019-02-26 | Gilead Sciences, Inc. | methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
BR102017010009A2 (en) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION |
JOP20190024A1 (en) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Substituted pyrrolizine compounds and uses thereof |
CA3035346A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
TWI820984B (en) | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | Crystalline forms of tenofovir alafenamide |
JOP20180008A1 (en) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | Compounds for the treatment of hepatitis b virus infection |
JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
CN111511754B (en) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 2'3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
EP3759109B1 (en) | 2018-02-26 | 2023-08-30 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds as hbv replication inhibitors |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TW202005654A (en) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2'2'-cyclic dinucleotides |
KR20200140867A (en) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-cyclic dinucleotide |
TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
CN108464984A (en) * | 2018-04-09 | 2018-08-31 | 徐州维康生物科技有限公司 | A kind of epigenetic drug for treating osteosarcoma |
CN108186643B (en) * | 2018-04-09 | 2021-04-20 | 徐州维康生物科技有限公司 | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TW202014193A (en) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 2’3’-cyclic dinucleotides comprising carbocyclic nucleotide |
CN108530381B (en) * | 2018-05-07 | 2021-09-21 | 上海科技大学 | Method for preparing diamine derivative from amide ester |
JP7105359B2 (en) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | PD-1/PD-L1 inhibitor |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
CA3106548A1 (en) * | 2018-08-06 | 2020-02-13 | Dana-Farber Cancer Institute, Inc. | Histone demethylase 5 inhibitors and uses thereof |
CN109234313A (en) * | 2018-09-25 | 2019-01-18 | 上海交通大学医学院附属第九人民医院 | Cotransfection carrier and its application in anti-bone and flesh tumor medicine |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TWI721623B (en) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | Substituted 6-azabenzimidazole compounds |
TWI721624B (en) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | Substituted 6-azabenzimidazole compounds |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
DK3934757T3 (en) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-CYCLIC DINUCLEOTIDES AND THEIR PRODUCTS |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
TWI751517B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TWI751516B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TWI826690B (en) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | Substituted eneoxindoles and uses thereof |
MX2021015452A (en) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use. |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
CN110652589A (en) * | 2019-10-12 | 2020-01-07 | 中国人民解放军陆军军医大学 | Application of GASC1 inhibitor in preparation of medicine for treating liver cancer |
CN116057068A (en) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | Optimized engineered meganucleases with specificity for recognition sequences in hepatitis b virus genomes |
CN111073900B (en) * | 2019-12-09 | 2023-05-02 | 温氏食品集团股份有限公司 | Method for improving development efficiency of pig cloned embryo |
AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
US20230203445A1 (en) | 2020-05-26 | 2023-06-29 | Healios K.K. | Hypoimmunogenic cells |
PE20230779A1 (en) | 2020-08-07 | 2023-05-09 | Gilead Sciences Inc | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE |
CN111905102A (en) * | 2020-09-04 | 2020-11-10 | 福建医科大学附属第一医院 | Use of EZH2 inhibitors for the treatment of gliomas |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN114907317B (en) * | 2022-06-01 | 2023-06-13 | 郑州大学 | Pyrazole-vinyl-isonicotinic acid derivative and preparation method and application thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
GB8717374D0 (en) * | 1987-07-22 | 1987-08-26 | Smith Kline French Lab | Pharmaceutically active compounds |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
JP2001500851A (en) | 1996-08-30 | 2001-01-23 | ノバルティス アクチエンゲゼルシャフト | Process for producing epothilone and intermediate products obtained during the process |
WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
US5874438A (en) | 1996-10-11 | 1999-02-23 | Bayer Aktiengesellschaft | 2,2'-bridged bis-2,4-diaminoquinazolines |
PT941227E (en) | 1996-11-18 | 2004-08-31 | Biotechnolog Forschung Mbh Gbf | EPOTHILONE AND ITS PREPARATION AND ITS USE AS A CITOSTATIC AGENT OR AS A PHYTOSANITARY PROTECTION AGENT |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (en) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | Synthesis of epothilone, its intermediates and analogs |
AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
US6620811B2 (en) * | 2001-11-19 | 2003-09-16 | Hoffmann-La Roche Inc. | Isonicotin- and nicotinamide derivatives of benzothiazoles |
ES2407849T3 (en) | 2002-03-13 | 2013-06-14 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
JP2008503469A (en) * | 2004-06-17 | 2008-02-07 | ワイス | Gonadotropin releasing hormone receptor antagonist |
WO2008002671A2 (en) | 2006-06-29 | 2008-01-03 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
EP2269990A4 (en) * | 2008-03-25 | 2012-04-18 | Takeda Pharmaceutical | Heterocyclic compound |
SA109300195B1 (en) | 2008-03-28 | 2013-04-20 | Astrazeneca Ab | A Novel Anti-Cancer Pharmaceutical Composition |
WO2010056549A1 (en) * | 2008-10-29 | 2010-05-20 | Sirtris Pharmaceuticals, Inc. | Pyridine, bicyclic pyridine and related analogs as sirtuin modulators |
WO2011017583A1 (en) | 2009-08-07 | 2011-02-10 | The Wistar Institute | Compositions containing jarid1b inhibitors and methods for treating cancer |
UA108618C2 (en) | 2009-08-07 | 2015-05-25 | APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT | |
MX347851B (en) | 2010-03-10 | 2017-05-16 | Incyte Corp | Piperidin-4-yl azetidine derivatives as jak1 inhibitors. |
US9365553B2 (en) * | 2010-05-27 | 2016-06-14 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and H1 receptor antagonist |
WO2012007008A1 (en) | 2010-07-15 | 2012-01-19 | Epitherapeutics Aps | Inhibitors of hdme |
US20130303545A1 (en) | 2010-09-30 | 2013-11-14 | Tamara Maes | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012047156A1 (en) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases |
WO2012071469A2 (en) | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
EP2688568B1 (en) | 2011-03-25 | 2019-06-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Cyclopropylamines as lsd1 inhibitors |
SI2744330T1 (en) | 2011-08-15 | 2020-11-30 | University Of Utah Research Foundation | Substituted (e)-n'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhiitors |
TW201323419A (en) * | 2011-10-27 | 2013-06-16 | Astellas Pharma Inc | Aminoalkyl-substituted N-thienylbenzamide derivative |
JP6164556B2 (en) * | 2011-12-01 | 2017-07-19 | 国立大学法人 千葉大学 | Drug for producing radiolabeled polypeptide with reduced nonspecific renal accumulation |
CN102585150B (en) | 2012-02-01 | 2013-09-04 | 嘉兴学院 | Preparation method of anionic aqueous polyurethane dispersoid for fabric coating and decoration |
WO2013123411A1 (en) | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
WO2013129435A1 (en) * | 2012-02-28 | 2013-09-06 | 協和発酵キリン株式会社 | Fused thiophene derivative |
CA2885969C (en) | 2012-10-02 | 2021-04-06 | Epitherapeutics Aps | Substitued pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases |
US9604961B2 (en) | 2012-12-06 | 2017-03-28 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
EP2934145B1 (en) | 2012-12-19 | 2017-11-15 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
PE20151417A1 (en) | 2012-12-21 | 2015-10-10 | Quanticel Pharmaceuticals Inc | HISTONE DESMETILASE INHIBITORS |
US9650339B2 (en) | 2013-02-27 | 2017-05-16 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
PL2970211T3 (en) | 2013-03-15 | 2018-01-31 | Quanticel Pharmaceuticals Inc | Histone demethylase inhibitors |
EP3041474B1 (en) | 2013-09-05 | 2020-03-18 | Genentech, Inc. | Antiproliferative compounds |
EP3126345A1 (en) | 2014-03-31 | 2017-02-08 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
-
2013
- 2013-10-01 CA CA2885969A patent/CA2885969C/en active Active
- 2013-10-01 CA CA3095019A patent/CA3095019C/en active Active
- 2013-10-01 SI SI201330511A patent/SI2903968T1/en unknown
- 2013-10-01 CN CN201710513194.9A patent/CN107434803B/en active Active
- 2013-10-01 SG SG10201703682YA patent/SG10201703682YA/en unknown
- 2013-10-01 DK DK13770928.3T patent/DK2903968T3/en active
- 2013-10-01 EP EP13770928.3A patent/EP2903968B1/en active Active
- 2013-10-01 PL PL13770928T patent/PL2903968T3/en unknown
- 2013-10-01 SG SG11201502452RA patent/SG11201502452RA/en unknown
- 2013-10-01 RS RS20170216A patent/RS55764B1/en unknown
- 2013-10-01 MD MDA20150043A patent/MD20150043A2/en not_active Application Discontinuation
- 2013-10-01 LT LTEP13770928.3T patent/LT2903968T/en unknown
- 2013-10-01 ME MEP-2017-46A patent/ME02597B/en unknown
- 2013-10-01 WO PCT/EP2013/070457 patent/WO2014053491A1/en active Application Filing
- 2013-10-01 HU HUE13770928A patent/HUE033380T2/en unknown
- 2013-10-01 JP JP2015534985A patent/JP6530313B2/en active Active
- 2013-10-01 PT PT152006722T patent/PT3023415T/en unknown
- 2013-10-01 ES ES13770928.3T patent/ES2617905T3/en active Active
- 2013-10-01 CN CN201380059974.0A patent/CN104981458B/en active Active
- 2013-10-01 EP EP15200672.2A patent/EP3023415B1/en active Active
- 2013-10-01 PL PL15200672T patent/PL3023415T3/en unknown
- 2013-10-01 EP EP16186022.6A patent/EP3150582A1/en not_active Withdrawn
- 2013-10-01 SI SI201330878T patent/SI3023415T1/en unknown
- 2013-10-01 PT PT137709283T patent/PT2903968T/en unknown
- 2013-10-01 EA EA201500394A patent/EA030698B1/en not_active IP Right Cessation
- 2013-10-01 AP AP2015008389A patent/AP2015008389A0/en unknown
- 2013-10-01 NZ NZ706635A patent/NZ706635A/en not_active IP Right Cessation
- 2013-10-01 PE PE2015000454A patent/PE20150998A1/en not_active Application Discontinuation
- 2013-10-01 BR BR112015007083A patent/BR112015007083A2/en active Search and Examination
- 2013-10-01 KR KR1020157011211A patent/KR102160320B1/en active IP Right Grant
- 2013-10-01 MX MX2015003959A patent/MX2015003959A/en unknown
- 2013-10-01 ES ES15200672.2T patent/ES2654143T3/en active Active
- 2013-10-01 US US14/381,558 patent/US20150203453A1/en active Granted
-
2014
- 2014-08-28 US US14/472,059 patent/US10189787B2/en active Active
-
2015
- 2015-03-19 IL IL237831A patent/IL237831A/en not_active IP Right Cessation
- 2015-04-01 PH PH12015500730A patent/PH12015500730A1/en unknown
- 2015-04-01 CL CL2015000829A patent/CL2015000829A1/en unknown
- 2015-04-28 CR CR20150217A patent/CR20150217A/en unknown
- 2015-08-19 HK HK15108027.3A patent/HK1207373A1/en unknown
-
2016
- 2016-03-31 HK HK16103714.1A patent/HK1215710A1/en unknown
- 2016-10-14 HK HK16111877.7A patent/HK1223612A1/en unknown
-
2017
- 2017-02-16 SM SM201700109T patent/SMT201700109B/en unknown
- 2017-02-17 US US15/436,055 patent/US10221139B2/en active Active
- 2017-03-03 HR HRP20170358TT patent/HRP20170358T1/en unknown
- 2017-03-07 CY CY20171100297T patent/CY1118695T1/en unknown
- 2017-07-02 IL IL253259A patent/IL253259B/en not_active IP Right Cessation
- 2017-07-19 PH PH12017501306A patent/PH12017501306A1/en unknown
- 2017-11-07 JP JP2017214526A patent/JP2018016661A/en active Pending
-
2018
- 2018-02-06 AU AU2018200876A patent/AU2018200876C1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253259A0 (en) | Inhibitors of histone demethylases | |
HK1220460A1 (en) | Inhibitors of histone demethylases | |
HK1210611A1 (en) | Histone demethylase inhibitors | |
PL2934145T3 (en) | Histone demethylase inhibitors | |
EP2928471A4 (en) | Histone demethylase inhibitors | |
AP4029A (en) | Inhibitors of beta-secretase | |
IL236963A0 (en) | Inhibitors of beta-secretase | |
HK1247920A1 (en) | Inhibitors of histone demethylases | |
AU2013326554A1 (en) | Inhibitors of histone demethylases | |
PT2961736T (en) | Inhibitors of histone demethylases |